Back to results
US 2021/0172954 A1Published application
Diagnostic and prognostic marker for prostate cancer
AssigneeOnconostic Technologies, Inc.
InventorPartha RAY
Life of this patent
Estimating the term…
Abstract
Provided herein are methods for determining a diagnosis and/or prognosis for prostate cancer using the ratio of FOXC1:FOXA1 in a sample obtained from a subject.
Claims25
1-53. (canceled)
A method for treating a subject based on the prognosis of a prostate cancer in a subject diagnosed as having prostate cancer, comprising:
- (i) obtaining a tissue sample from said subject, wherein said tissue sample comprises prostate cancer cells;
- (ii) determining the level of FOXA1 protein or nucleic acid in said tissue sample,
- (iii) determining the level of FOXC1 protein or nucleic acid in said tissue sample,
- (iv) calculating the ratio of said FOXC1 protein or nucleic acid to said FOXA1 protein or nucleic acid;
- (v) comparing said ratio to a comparable FOXC1:FOXA1 ratio in a reference population of samples comprising prostate cancer cells in which a prognostic outcome is associated with each of the reference population samples;
- (vi) identifying said subject as having a poor prognosis relative to the prognostic outcome when the FOXC1:FOXA1 ratio of the subject is equal to or greater than a FOXC1:FOXA1 cutoff ratio, and identifying said subject as having a good prognosis relative to the prognostic outcome when the FOXC1:FOXA1 ratio of the subject is less than the FOXC1:FOXA1 cutoff ratio, wherein the FOXC1:FOXA1 cutoff ratio corresponds to at least the 50th percentile of FOXC1:FOXA1 ratios of the reference population;
- and
- (vii) treating said subject by discontinuing, maintaining, initiating, or modifying at least one anti-cancer therapy based on the prognosis identified in step (vi).
5 more elements
A method for treating a subject diagnosed with a prostate cancer, comprising:
- (i) obtaining a tissue sample from said subject, wherein said tissue sample is suspected of comprising prostate cancer cells;
- (ii) determining the level of FOXA1 protein or nucleic acid in said tissue sample,
- (iii) determining the level of FOXC1 protein or nucleic acid in said tissue sample,
- (iv) calculating the ratio of said FOXC1 protein or nucleic acid to said FOXA1 protein or nucleic acid;
- (v) comparing said ratio to a comparable FOXC1:FOXA1 ratio in a reference population of samples known to comprise prostate cancer cells;
- (vi) identifying said subject as having a prostate cancer when the FOXC1:FOXA1 ratio of the subject is equal to or greater than a FOXC1:FOXA1 cutoff ratio, and identifying said subject as not having a prostate cancer when the FOXC1:FOXA1 ratio of the subject is less than the FOXC1:FOXA1 cutoff ratio, wherein the FOXC1:FOXA1 cutoff ratio corresponds to at least the 20th percentile of FOXC1:FOXA1 ratios of the reference population;
- and
- (vii) treating the subject diagnosed with a prostate cancer by a chemotherapeutic agent or performing a surgical resection of the prostate, surrounding tissues, or distant tissues in which metastasis are expected or confirmed.
5 more elements
A method for determining and implementing a treatment plan in a subject diagnosed as having a prostate cancer, said method comprising:
- (i) obtaining a tissue sample from said subject, wherein said tissue sample comprises prostate cancer cells;
- (ii) determining the level of FOXA1 protein or nucleic acid in said tissue sample,
- (iii) determining the level of FOXC1 protein or nucleic acid in said tissue sample,
- (iv) calculating the ratio of said FOXC1 protein or nucleic acid to said FOXA1 protein or nucleic acid;
- (v) comparing said ratio to a comparable FOXC1:FOXA1 ratio in a reference population of samples known to comprise prostate cancer cells;
- and
- (vi) developing and implementing a treatment plan based on the comparison of step (v) for said subject as having a prostate cancer when the FOXC1:FOXA1 ratio of the subject is equal to or greater than a FOXC1:FOXA1 cutoff ratio, wherein the FOXC1:FOXA1 cutoff ratio corresponds to at least the 20th percentile of FOXC1:FOXA1 ratios of the reference population, wherein the treatment plan includes initiating a chemotherapy, initiating a radiation therapy, and surgical resection of the prostate, surrounding tissues, or distant tissues in which metastasis are expected or confirmed.
4 more elements
Dependencies are inferred from the claim text.